The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Interferon-γ signaling contributes to drug resistance in AML
Hussein Abbas, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the impact of inflammatory mediators on therapy responses and outcomes in acute myeloid leukemia (AML). Specifically, he highlights the role of interferon-γ in influencing T-cell activity and contributing to drug resistance, including resistance to venetoclax. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
